Document is current
Any future updates will be listed below
-
Authors
Wick, A.
Sander, A.
Koch, M.
Bendszus, M.
Combs, S.
Haut, T.
Dormann, A.
Walter, S.
Pertz, M.
Merkle-Lock, J.
Selkrig, N.
Limprecht, R.
Baumann, L.
Kieser, M.
Sahm, F.
Schlegel, U.
Winkler, F.
Platten, M.
Wick, W. http://orcid.org/0000-0002-6171-634X
Kessler, T.
-
Funding
Funding for this research was provided by:
BMBF (01KG1605)
Medizinische Fakultät Heidelberg der Universität Heidelberg
- License Information
-
More Information
Article History
Received: 19 April 2022
Accepted: 30 May 2022
First Online: 13 June 2022
Declarations
:
: The study was approved by the national regulatory authority (BfArM, Germany) and the institutional review board (Ethikkommission) at each initiated study site. The main Ethics Committee was Ethikkommission der Medizinischen Fakultät der Universität Heidelberg, Alte Glockengießerei 11/1, 69115 Heidelberg (AFmu-3892020). Each study patient gives written consent to the study participation. The current protocol version is 5.0, 15 Jul 2021.
: The manuscript does not contain any individual person’s data, hence this is not applicable.
: MP and WW are inventors and patent-holders on ‘Peptides for use in treating or diagnosing IDH1R132H positive cancers’ (EP2800580B1).
